Evaluation of the Inclusion of Studies Identified by the FDA as Having Falsified Data in the Results of Meta-analyses: The Example of the Apixaban Trials -

Evaluation of the Inclusion of Studies Identified by the FDA as Having Falsified Data in the Results of Meta-analyses: The Example of the Apixaban Trials
Information type: Other primary research
Source: JAMA Internal Medicine
Specialities: Cardiovascular system disorders
Summary
Research letter notes that ARISTOTLE clinical trial was identified in 22 meta-analyses and found 46% of all meta-analysis publications had conclusions altered by publications with falsified data, and 32% of all the analyses had a considerable change in the outcome.
UKMi comment
The authors warn that the desire to include all available data in a meta-analysis to obtain the “best estimate” of effect size may result in the inclusion of falsified data, which may compromise future research, policy decisions, and patient care.
Related links: